Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial
- 1 April 1993
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 341 (8852), 1051-1054
- https://doi.org/10.1016/0140-6736(93)92411-l
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Mini‐BEAM followed by BEAM and ABMT for very poor risk Hodgkin's diseaseBritish Journal of Haematology, 1992
- Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.Journal of Clinical Oncology, 1991
- Is there an effective salvage therapy for advanced Hodgkin's disease?Annals of Oncology, 1991
- Mini-beam as Salvage Chemotherapy for Refractory Hodgkin's Disease and Non-Hodgkin's LymphomaLeukemia & Lymphoma, 1991
- Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.Journal of Clinical Oncology, 1990
- High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's diseaseBritish Journal of Cancer, 1989
- High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.Journal of Clinical Oncology, 1988
- The potential value of very intensive therapy with autologous bone marrow rescue in the treatment of malignant lymphomasHematological Oncology, 1987
- Tables of the number of patients required in clinical trials using the logrank testStatistics in Medicine, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958